Merck & Co.'s Revenue
- Merck & Co.'s annual revenue was $60.12B in fiscal year 2023. The annual revenue increased $832.00M from $59.28B (in 2022) to $60.12B (in 2023), representing a 1.40% year-over-year growth.
- Merck & Co.'s quarterly revenue was $16.66B in the quarter ending Sep 2024. The quarterly revenue increased $695.00M from $15.96B (in Q3: June 2023) to $16.66B (in Q3: June 2024), representing a 4.35% year-over-year growth.
- The highest annual revenue for Merck & Co. was $60.12B in fiscal year 2023.
- The lowest annual revenue was $39.50B in fiscal year 2015.
- The average revenue was $46.46B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2015 - 2024):
Learn more about Merck & Co.'s Revenue by Segment and Revenue by Region.
Check out competitors to Merck & Co. in a side-by-side comparison.
Explore additional financial metrics for Merck & Co..
Definition of Revenue :
| 2014 | 42237000000.00 |
|---|---|
| 2015 | 39498000000.00 |
| 2016 | 39807000000.00 |
| 2017 | 40122000000.00 |
| 2018 | 42294000000.00 |
| 2019 | 46840000000.00 |
| 2020 | 41518000000.00 |
| 2021 | 48704000000.00 |
| 2022 | 59283000000.00 |
| 2023 | 60115000000.00 |
| Mar 2015 | 9425000000.00 |
|---|---|
| Jun 2015 | 9785000000.00 |
| Sep 2015 | 10073000000.00 |
| Dec 2015 | 10215000000.00 |
| Mar 2016 | 9312000000.00 |
| Jun 2016 | 9844000000.00 |
| Sep 2016 | 10536000000.00 |
| Dec 2016 | 10115000000.00 |
| Mar 2017 | 9434000000.00 |
| Jun 2017 | 9930000000.00 |
| Sep 2017 | 10325000000.00 |
| Dec 2017 | 10433000000.00 |
| Mar 2018 | 10037000000.00 |
| Jun 2018 | 10465000000.00 |
| Sep 2018 | 10794000000.00 |
| Dec 2018 | 10998000000.00 |
| Mar 2019 | 10816000000.00 |
| Jun 2019 | 11760000000.00 |
| Sep 2019 | 12397000000.00 |
| Dec 2019 | 11868000000.00 |
| Mar 2020 | 12057000000.00 |
| Jun 2020 | 9353000000.00 |
| Sep 2020 | 10929000000.00 |
| Dec 2020 | 12515000000.00 |
| Mar 2021 | 10627000000.00 |
| Jun 2021 | 11402000000.00 |
| Sep 2021 | 13154000000.00 |
| Dec 2021 | 13521000000.00 |
| Mar 2022 | 15901000000.00 |
| Jun 2022 | 14593000000.00 |
| Sep 2022 | 14959000000.00 |
| Dec 2022 | 13830000000.00 |
| Mar 2023 | 14487000000.00 |
| Jun 2023 | 15035000000.00 |
| Sep 2023 | 15962000000.00 |
| Dec 2023 | 14630000000.00 |
| Mar 2024 | 15775000000.00 |
| Jun 2024 | 16156000000.00 |
| Sep 2024 | 16657000000.00 |
2023
Merck & Co.'s annual revenue was $60.12B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $14.49B(Q1: Mar 2023), $15.04B(Q2: Jun 2023), $15.96B(Q3: Sep 2023), $14.63B(Q4: Dec 2023) in fiscal year 2023.
2022
Merck & Co.'s annual revenue was $59.28B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $15.90B(Q1: Mar 2022), $14.59B(Q2: Jun 2022), $14.96B(Q3: Sep 2022), $13.83B(Q4: Dec 2022) in fiscal year 2022.
2021
Merck & Co.'s annual revenue was $48.70B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $10.63B(Q1: Mar 2021), $11.40B(Q2: Jun 2021), $13.15B(Q3: Sep 2021), $13.52B(Q4: Dec 2021) in fiscal year 2021.
2020
Merck & Co.'s annual revenue was $41.52B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $12.06B(Q1: Mar 2020), $9.35B(Q2: Jun 2020), $10.93B(Q3: Sep 2020), $12.52B(Q4: Dec 2020) in fiscal year 2020.
2019
Merck & Co.'s annual revenue was $46.84B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $10.82B(Q1: Mar 2019), $11.76B(Q2: Jun 2019), $12.40B(Q3: Sep 2019), $11.87B(Q4: Dec 2019) in fiscal year 2019.
2018
Merck & Co.'s annual revenue was $42.29B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $10.04B(Q1: Mar 2018), $10.47B(Q2: Jun 2018), $10.79B(Q3: Sep 2018), $11.00B(Q4: Dec 2018) in fiscal year 2018.
2017
Merck & Co.'s annual revenue was $40.12B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $9.43B(Q1: Mar 2017), $9.93B(Q2: Jun 2017), $10.33B(Q3: Sep 2017), $10.43B(Q4: Dec 2017) in fiscal year 2017.
2016
Merck & Co.'s annual revenue was $39.81B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $9.31B(Q1: Mar 2016), $9.84B(Q2: Jun 2016), $10.54B(Q3: Sep 2016), $10.12B(Q4: Dec 2016) in fiscal year 2016.
2015
Merck & Co.'s annual revenue was $39.50B in fiscal year 2023.
Merck & Co.'s quarterly revenue was $9.43B(Q1: Mar 2015), $9.79B(Q2: Jun 2015), $10.07B(Q3: Sep 2015), $10.22B(Q4: Dec 2015) in fiscal year 2015.
| 2014 | 0 |
|---|---|
| 2015 | -6.48 |
| 2016 | +0.78 |
| 2017 | +0.79 |
| 2018 | +5.41 |
| 2019 | +10.75 |
| 2020 | -11.36 |
| 2021 | +17.31 |
| 2022 | +21.72 |
| 2023 | +1.40 |
| Q1: Mar 15 | -8.17 |
|---|---|
| Q2: Jun 15 | -10.51 |
| Q3: Sep 15 | -4.58 |
| Q4: Dec 15 | -2.55 |
| Q1: Mar 16 | -1.20 |
| Q2: Jun 16 | 0.60 |
| Q3: Sep 16 | 4.60 |
| Q4: Dec 16 | -0.98 |
| Q1: Mar 17 | 1.31 |
| Q2: Jun 17 | 0.87 |
| Q3: Sep 17 | -2.00 |
| Q4: Dec 17 | 3.14 |
| Q1: Mar 18 | 6.39 |
| Q2: Jun 18 | 5.39 |
| Q3: Sep 18 | 4.54 |
| Q4: Dec 18 | 5.42 |
| Q1: Mar 19 | 7.76 |
| Q2: Jun 19 | 12.37 |
| Q3: Sep 19 | 14.85 |
| Q4: Dec 19 | 7.91 |
| Q1: Mar 20 | 11.47 |
| Q2: Jun 20 | -20.47 |
| Q3: Sep 20 | -11.84 |
| Q4: Dec 20 | 5.45 |
| Q1: Mar 21 | -11.86 |
| Q2: Jun 21 | 21.91 |
| Q3: Sep 21 | 20.36 |
| Q4: Dec 21 | 8.04 |
| Q1: Mar 22 | 49.63 |
| Q2: Jun 22 | 27.99 |
| Q3: Sep 22 | 13.72 |
| Q4: Dec 22 | 2.29 |
| Q1: Mar 23 | -8.89 |
| Q2: Jun 23 | 3.03 |
| Q3: Sep 23 | 6.70 |
| Q4: Dec 23 | 5.78 |
| Q1: Mar 24 | 8.89 |
| Q2: Jun 24 | 7.46 |
| Q3: Sep 24 | 4.35 |
2023
Merck & Co.’s annual revenue increased +1.40% during fiscal year 2023 compared to 2022. It represents a growth of $832.00M from $59.28B (in 2022) to $60.12B (in 2023).
2022
Merck & Co.’s annual revenue increased +21.72% during fiscal year 2022 compared to 2021. It represents a growth of $10.58B from $48.70B (in 2021) to $59.28B (in 2022).
2021
Merck & Co.’s annual revenue increased +17.31% during fiscal year 2021 compared to 2020. It represents a growth of $7.19B from $41.52B (in 2020) to $48.70B (in 2021).
2020
Merck & Co.’s annual revenue decreased -11.36% during fiscal year 2020 compared to 2019. It represents a decline of -$5.32B from $46.84B (in 2019) to $41.52B (in 2020).
2019
Merck & Co.’s annual revenue increased +10.75% during fiscal year 2019 compared to 2018. It represents a growth of $4.55B from $42.29B (in 2018) to $46.84B (in 2019).
2018
Merck & Co.’s annual revenue increased +5.41% during fiscal year 2018 compared to 2017. It represents a growth of $2.17B from $40.12B (in 2017) to $42.29B (in 2018).
2017
Merck & Co.’s annual revenue increased +0.79% during fiscal year 2017 compared to 2016. It represents a growth of $315.00M from $39.81B (in 2016) to $40.12B (in 2017).
2016
Merck & Co.’s annual revenue increased +0.78% during fiscal year 2016 compared to 2015. It represents a growth of $309.00M from $39.50B (in 2015) to $39.81B (in 2016).
2015
Merck & Co.’s annual revenue decreased -6.48% during fiscal year 2015 compared to 2014. It represents a decline of -$2.74B from $42.24B (in 2014) to $39.50B (in 2015).
Summary Table (Annual)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| 2023 | $60.12B | +1.40% |
| 2022 | $59.28B | +21.72% |
| 2021 | $48.70B | +17.31% |
| 2020 | $41.52B | -11.36% |
| 2019 | $46.84B | +10.75% |
| 2018 | $42.29B | +5.41% |
| 2017 | $40.12B | +0.79% |
| 2016 | $39.81B | +0.78% |
| 2015 | $39.50B | -6.48% |
Summary Table (Quarterly)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q3: Sep 24 | $16.66B | 4.35% |
| Q2: Jun 24 | $16.16B | 7.46% |
| Q1: Mar 24 | $15.78B | 8.89% |
| Q4: Dec 23 | $14.63B | 5.78% |
| Q3: Sep 23 | $15.96B | 6.70% |
| Q2: Jun 23 | $15.04B | 3.03% |
| Q1: Mar 23 | $14.49B | -8.89% |
| Q4: Dec 22 | $13.83B | 2.29% |
| Q3: Sep 22 | $14.96B | 13.72% |
| Q2: Jun 22 | $14.59B | 27.99% |
| Q1: Mar 22 | $15.90B | 49.63% |
| Q4: Dec 21 | $13.52B | 8.04% |
| Q3: Sep 21 | $13.15B | 20.36% |
| Q2: Jun 21 | $11.40B | 21.91% |
| Q1: Mar 21 | $10.63B | -11.86% |
| Q4: Dec 20 | $12.52B | 5.45% |
| Q3: Sep 20 | $10.93B | -11.84% |
| Q2: Jun 20 | $9.35B | -20.47% |
| Q1: Mar 20 | $12.06B | 11.47% |
| Q4: Dec 19 | $11.87B | 7.91% |
| Q3: Sep 19 | $12.40B | 14.85% |
| Q2: Jun 19 | $11.76B | 12.37% |
| Q1: Mar 19 | $10.82B | 7.76% |
| Q4: Dec 18 | $11.00B | 5.42% |
| Q3: Sep 18 | $10.79B | 4.54% |
| Q2: Jun 18 | $10.47B | 5.39% |
| Q1: Mar 18 | $10.04B | 6.39% |
| Q4: Dec 17 | $10.43B | 3.14% |
| Q3: Sep 17 | $10.33B | -2.00% |
| Q2: Jun 17 | $9.93B | 0.87% |
| Q1: Mar 17 | $9.43B | 1.31% |
| Q4: Dec 16 | $10.12B | -0.98% |
| Q3: Sep 16 | $10.54B | 4.60% |
| Q2: Jun 16 | $9.84B | 0.60% |
| Q1: Mar 16 | $9.31B | -1.20% |
| Q4: Dec 15 | $10.22B | -2.55% |
| Q3: Sep 15 | $10.07B | -4.58% |
| Q2: Jun 15 | $9.79B | -10.51% |
| Q1: Mar 15 | $9.43B | -8.17% |
Related company
Related
-
Agilent Technologies Revenue
-
Eli Lilly and Company Revenue
-
Stryker Corporation Revenue
-
Johnson & Johnson Revenue
-
AbbVie Revenue
-
Thermo Fisher Scientific Revenue
-
Abbott Laboratories Revenue
-
Danaher Corporation Revenue
-
Amgen Revenue
-
Pfizer Revenue
-
Boston Scientific Corporation Revenue
-
Bristol-Myers Squibb Company Revenue
-
Cigna Corporation Revenue
-
McKesson Corporation Revenue
-
Cardinal Health Revenue
-
Moderna Revenue
